This protocol addresses recurrent epithelial ovarian cancer in patients whose disease has become platinum-resistant — defined as progression on primary, maintenance, or recurrence therapy; stable or persistent disease in a patient not currently on maintenance therapy; or a complete remission that is followed by relapse within 6 months of completing chemotherapy.
Platinum resistance is established when disease progresses during or despite platinum-based treatment, or when remission proves short-lived — relapse occurring under 6 months after the last chemotherapy cycle. Meeting these criteria identifies the sub-population for whom the options covered here are relevant.
Subsequent recurrence therapy in this setting is guided by tumour biomarker profiling. The approach includes biomarker-directed immunotherapy and targeted agents chosen according to the specific molecular profile of the tumour. The complete selection algorithm, eligibility criteria, and individual regimen details are available in the full protocol.